{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T03:02:40Z","timestamp":1789786960312,"version":"4.0.1"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.jpba.2026.117692","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:48:03Z","timestamp":1785858483000},"page":"117692","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["An analytical quality by design-guided method development for the quantification of N-nitroso-fluoxetine to support mitigation strategies for a fluoxetine drug product"],"prefix":"10.1016","volume":"282","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0162-6158","authenticated-orcid":false,"given":"Yue","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Yves","family":"Sacr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Streel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6117-2031","authenticated-orcid":false,"given":"Eric","family":"Ziemons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4941-3052","authenticated-orcid":false,"given":"Philippe","family":"Hubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9127-7106","authenticated-orcid":false,"given":"C\u00e9dric","family":"Hubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2026.117692_bib1","unstructured":"U.S. Food & Drug Administration, FDA Updates and Press Announcements on Nitrosamine in Varenicline (Chantix), (2022). https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-updates-and-press-announcements-nitrosamine-varenicline-chantix#:\u223c:text=Update %5B9%2F17%2F2021,N-nitroso-varenicline levels. (accessed January 26, 2026)."},{"key":"10.1016\/j.jpba.2026.117692_bib2","unstructured":"European Medicines Agency, Acceptable intakes (AIs) established for N-nitrosamines, EMA\/CHMP\/42189\/2026\/Rev. 12, 2026."},{"key":"10.1016\/j.jpba.2026.117692_bib3","unstructured":"Health Sciences Authority, Recall of Fluoxone Divule (fluoxetine) 20mg Tablet, (2023). https:\/\/www.hsa.gov.sg\/announcements\/product-recall\/recall-of-fluoxone-divule-(fluoxetine)-20mg-tablet (accessed March 6, 2025)."},{"key":"10.1016\/j.jpba.2026.117692_bib4","unstructured":"Health Sciences Authority, Recall of Proctin 20mg Capsule (Fluoxetine), (2024). https:\/\/www.hsa.gov.sg\/announcements\/product-recall\/recall-of-proctin-20mg-capsule-(fluoxetine)#:\u223c:text=Retail-level recall of one,impurity above the acceptable level.&text=Description of Issue%3A,be above the acceptable level. (accessed March 6, 2025)."},{"key":"10.1016\/j.jpba.2026.117692_bib5","unstructured":"Health Products Regulatory Authority, Fluzac 20mg Capsules \u2013 PA711\/110\/1 \u2013 Multiple batches, (2024). https:\/\/www.hpra.ie\/safety-information\/safety-notices\/article\/recall-of-a-number-of-batches-of-fluzac-20mg-capsules--pa711-110-1 (accessed March 6, 2025)."},{"key":"10.1016\/j.jpba.2026.117692_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2024.105640","article-title":"Determining recommended acceptable intake limits for N-nitrosamine impurities in pharmaceuticals: Development and application of the Carcinogenic Potency Categorization Approach (CPCA)","volume":"150","author":"Kruhlak","year":"2024","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.jpba.2026.117692_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2023.115880","article-title":"The quality of drugs and drug products \u2013 Always guaranteed?","volume":"239","author":"Buschmann","year":"2024","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2026.117692_bib8","article-title":"Questions and answers for marketing authorisation holders\/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726\/2004 referral on nitrosamine impurities in human medicinal products","volume":"23","author":"European Medicines Agency","year":"2025"},{"key":"10.1016\/j.jpba.2026.117692_bib9","unstructured":"U.S. Food & Drug Administration, CDER Nitrosamine Impurity Acceptable Intake Limits, (2025). https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/cder-nitrosamine-impurity-acceptable-intake-limits (accessed January 21, 2026)."},{"key":"10.1016\/j.jpba.2026.117692_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2026.106036","article-title":"Nitrosamine Drug Substance-Related Impurities cause DNA methylation adducts in vitro and in primary hepatocytes upon Cytochrome P450-dependend metabolic activation","volume":"167","author":"Vogel","year":"2026","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.jpba.2026.117692_bib11","unstructured":"Federal Agency for Medicines and Health Products, PharmaStatus: Fluoxone Divule 20 mg coat. tabl. 100, PharmaStatus (2023). https:\/\/pharmastatus.be\/medical-products\/64224 (accessed March 9, 2026)."},{"key":"10.1016\/j.jpba.2026.117692_bib12","unstructured":"Federal Agency for Medicines and Health Products, PharmaStatus: Fluoxone Divule 20 mg coat. tabl. 30, PharmaStatus (2023). https:\/\/pharmastatus.be\/medical-products\/cti\/237955-01 (accessed March 9, 2026)."},{"key":"10.1016\/j.jpba.2026.117692_bib13","unstructured":"Association pharmaceutique belge, Retraits Fluoxone divule, (2023). https:\/\/www.apb.be\/fr-BE\/Article\/fluoxone-divule\u223c813FR (accessed March 9, 2026)."},{"key":"10.1016\/j.jpba.2026.117692_bib14","unstructured":"U.S. Food & Drug Administration, Pharmaceutical cGMPs for the 21st century - A risk-based approach, 2004."},{"key":"10.1016\/j.jpba.2026.117692_bib15","unstructured":"The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, ICH Q8(R2) Pharmaceutical development, 2009."},{"key":"10.1016\/j.jpba.2026.117692_bib16","unstructured":"The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, ICH Q9 Quality risk management, 2023."},{"key":"10.1016\/j.jpba.2026.117692_bib17","article-title":"The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use","year":"2024","journal-title":"ICH Q14 Anal. Proced. Dev."},{"key":"10.1016\/j.jpba.2026.117692_bib18","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ejpb.2019.12.007","article-title":"Quality by design in pharmaceutical manufacturing: a systematic review of current status, challenges and future perspectives","volume":"147","author":"Grangeia","year":"2020","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jpba.2026.117692_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2022.114867","article-title":"Simultaneous determination of 13 nitrosamine impurities in biological medicines using salting-out liquid-liquid extraction coupled with liquid chromatography tandem mass spectrometry","volume":"218","author":"Luo","year":"2022","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2026.117692_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2021.113960","article-title":"Analytical lifecycle management for comprehensive and universal nitrosamine analysis in various pharmaceutical formulations by supercritical fluid chromatography","volume":"197","author":"Schmidtsdorff","year":"2021","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2026.117692_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2024.116303","article-title":"Investigation into the genotoxic impurity, 1-methyl-4-nitrosopiperazine, in rifampicin","volume":"248","author":"Tian","year":"2024","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2026.117692_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2023.115861","article-title":"Comprehensive UHPLC\u2013MS screening methods for the analysis of triazolopyrazine precursor and its genotoxic nitroso-derivative in sitagliptin pharmaceutical formulation","volume":"238","author":"Jire\u0161","year":"2024","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2026.117692_bib23","unstructured":"Taiwan Food and Drug Administration, Method of test for N-nitroso fluoxetine in fluoxetine drug substance, (2024). https:\/\/www.fda.gov.tw\/ENG\/siteList.aspx?sid=10360 (accessed January 29, 2026)."},{"key":"10.1016\/j.jpba.2026.117692_bib24","unstructured":"Landesamt f\u00fcr Gesundheit und Lebensmittelsicherheit, N-Nitroso-Fluoxetine in Fluoxetine tablets, (2023). https:\/\/www.edqm.eu\/documents\/52006\/1925123\/LGL+method+-+LC-MS+MS+method+for+the+determination+of+N-Nitroso-Fluoxetine+in+Fluoxetine+tablets.pdf\/c2d4b277-be30-d2d1-fd6c-733f97a77d86?t=1707294155615 (accessed March 29, 2026)."},{"key":"10.1016\/j.jpba.2026.117692_bib25","unstructured":"S.M.B. Laboratoire, Summary of product characteristics - Fluoxone\u00ae 20 mg, 2025."},{"key":"10.1016\/j.jpba.2026.117692_bib26","unstructured":"DFE pharma, Nitrosamine risk calculator, (2025). https:\/\/dfepharma.com\/nitrosamine-risk-calculator\/ (accessed January 28, 2026)."},{"key":"10.1016\/j.jpba.2026.117692_bib27","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.xphs.2022.04.016","article-title":"A nitrite excipient database: a useful tool to support N-nitrosamine risk assessments for drug products","volume":"112","author":"Boetzel","year":"2023","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jpba.2026.117692_bib28","article-title":"Sustainability of blisters for medicines in tablet form","volume":"21","author":"Pedrosa de Oliveira","year":"2021","journal-title":"Sustain. Chem. Pharm."},{"key":"10.1016\/j.jpba.2026.117692_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2023.105355","article-title":"A comprehensive review of sources of nitrosamine contamination of pharmaceutical substances and products","volume":"139","author":"Akkaraju","year":"2023","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.jpba.2026.117692_bib30","article-title":"Nitrosamines crisis in pharmaceuticals \u2212 Insights on toxicological implications, root causes and risk assessment: a systematic review","volume":"14","author":"Vikram","year":"2024","journal-title":"J. Pharm. Anal."},{"key":"10.1016\/j.jpba.2026.117692_bib31","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.chroma.2014.01.009","article-title":"Simultaneous determination of volatile and non-volatile nitrosamines in processed meat products by liquid chromatography tandem mass spectrometry using atmospheric pressure chemical ionisation and electrospray ionisation","volume":"1330","author":"Herrmann","year":"2014","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.jpba.2026.117692_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/frans.2026.1772719","article-title":"A case study on N-nitrosamine investigation in a marketed drug: from analytical procedure validation to risk mitigation decision","volume":"6","author":"Zhang","year":"2026","journal-title":"Front. Anal. Sci."},{"key":"10.1016\/j.jpba.2026.117692_bib33","unstructured":"The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, ICH Q2(R2) Validation of analytical procedures, 2024."},{"key":"10.1016\/j.jpba.2026.117692_bib34","article-title":"Innovative QSRR modeling approach for the development of an ultra-sensitive LC-MS\/MS method for trace analysis of N-nitrosamines","volume":"5","author":"Zhang","year":"2025","journal-title":"J. Pharm. Biomed. Anal. Open."},{"key":"10.1016\/j.jpba.2026.117692_bib35","unstructured":"U.S. Food & Drug Administration, Liquid Chromatography-Electrospray Ionization-High Resolution Mass Spectrometry (LC-ESI-HRMS) Method for the Determination of Nitrosamine Impurities in Metformin Drug Substance and Drug Product, (2020). https:\/\/www.fda.gov\/media\/138617\/download (accessed April 23, 2026)."},{"key":"10.1016\/j.jpba.2026.117692_bib36","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.aca.2007.04.002","article-title":"Improvement of the decision efficiency of the accuracy profile by means of a desirability function for analytical methods validation. Application to a diacetyl-monoxime colorimetric assay used for the determination of urea in transdermal iontophoretic ext","volume":"591","author":"Rozet","year":"2007","journal-title":"Anal. Chim. Acta"},{"key":"10.1016\/j.jpba.2026.117692_bib37","first-page":"70","article-title":"Harmonization of strategies for the validation of quantitative analytical procedures","volume":"45","author":"Hubert","year":"2007","journal-title":"A SFSTP Propos. - Part. II J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2026.117692_bib38","unstructured":"United States Pharmacopeial Convention, <1058> Analytical instrument qualification, in: United States Pharmacop., 2017."},{"key":"10.1016\/j.jpba.2026.117692_bib39","unstructured":"European Directorate for the Quality of Medicines & HealthCare, 2.2.46. Chromatographic separation techniques, in: Eur. Pharmacopoeia, 11.6, 2025: p. 01\/2025:20246."},{"key":"10.1016\/j.jpba.2026.117692_bib40","article-title":"A review on characterization and recyclability of pharmaceutical blisters","volume":"4","author":"Yaren \u00c7apk\u0131n","year":"2023","journal-title":"Clean. Waste Syst."},{"key":"10.1016\/j.jpba.2026.117692_bib41","first-page":"663","article-title":"Pharmaceutical packaging: recent trends and challenges","volume":"1","author":"Sah","year":"2024"},{"key":"10.1016\/j.jpba.2026.117692_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.trac.2021.116223","article-title":"White analytical chemistry: an approach to reconcile the principles of green analytical chemistry and functionality","volume":"138","author":"Nowak","year":"2021","journal-title":"TrAC. - Trends Anal. Chem."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708526003602?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708526003602?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T02:30:36Z","timestamp":1789785036000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708526003602"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":42,"alternative-id":["S0731708526003602"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2026.117692","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An analytical quality by design-guided method development for the quantification of N-nitroso-fluoxetine to support mitigation strategies for a fluoxetine drug product","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2026.117692","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117692"}}